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Abstract
Advanced stage hepatocellular carcinoma (HCC) is a 
category of disease defined by radiological, clinical and 
hepatic function parameters, comprehending a wide 
range of patients with different general conditions. The 
main therapeutic option is represented by sorafenib 
treatment, a multi-kinase inhibitor with anti-proliferative 
and anti-angiogenic effect. Trans-arterial Radio Embo-
lization also represents a promising new approach to 
intermediate/advanced HCC. Post-marketing clinical 
studies showed that only a portion of patients actually 
benefits from sorafenib treatment, and an even smaller 
percentage of patients treated shows partial/complete 
response on follow-up examinations, up against relevant 
costs and an incidence of drug related adverse effects. 
Although the treatment with sorafenib has shown a 
significant increase in mean overall survival in different 
studies, only a part of patients actually shows real 
benefits, while the incidence of drug related significant 
adverse effects and the economic costs are relatively 
high. Moreover, only a small percentage of patients 
also shows a response in terms of lesion dimensions 
reduction. Being able to properly differentiate patients 
who are responding to the therapy from non-responders 
as early as possible is then still difficult and could 
be a pivotal challenge for the future; in fact it could 
spare several patients a therapy often difficult to bear, 
directing them to other second line treatments (many of 
which are at the moment still under investigation). For 
this reason, some supplemental criteria to be added to 
the standard modified Response Evaluation Criteria 
in Solid Tumors evaluation are being searched for. In 
particular, finding some parameters (cellular density, 
perfusion grade and enhancement rate) able to predict 
the sensitivity of the lesions to anti-angiogenic agents 
could help in stratifying patients in terms of treatment 
responsiveness before the beginning of the therapy 
itself, or in the first weeks of sorafenib treatment. 
This would bring a strongly desirable help in clinical 
managements of these patients.
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Core tip: Advanced stage hepatocellular carcinoma 
comprehends a wide range of patients with different 
general conditions. The main therapeutic option is 
represented by sorafenib. Although the treatment has 
shown a significant increase in mean overall survival, only 
a part of patients actually shows benefits. Differentiating 
responder from non-responder patients is a pivotal 
challenge for the future. In particular, finding parameters 
quantitatively describing perfusion grade, and then able 
to predict the sensitivity of the lesions to anti-angiogenic 
agents could help stratifying patients in terms of 
responsiveness before the beginning of the therapy itself. 
This would bring a great help in management of these 
patients. 
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wjgnet.com/1948-5182/full/v7/i8/1041.htm  DOI: http://dx.doi.
org/10.4254/wjh.v7.i8.1041
INTRODUCTION
Hepatocellular carcinoma (HCC) represents the fifth 
most prevalent tumor worldwide and the third cause 
of cancer related death[1]. The feasibility of treatments 
and the linked prognosis largely vary because of the 
tumor characteristics that present wide variability in 
terms of local and extra-hepatic burden. Moreover, the 
differences in molecular features and aggressiveness 
of the tumor significantly influence the natural history 
of the disease. Finally, the management of HCC is 
also complicated, in the majority of patients, by its 
development on a background of a cirrhotic liver, that can 
compromise the viability of the appropriate treatment[2]. 
Advanced HCC represents a major problem, as a 
considerable portion of HCC is diagnosed at this stage 
despite the wide use of ultrasound for surveillance in 
patients with increased risk[3]. This stage of disease 
is related to a poor prognosis and is reported to be 
associated with a survival rate of about 25% at 1 
year[4,5]. Unfortunately, patients with advanced HCC 
are not suitable for curative therapeutic strategies like 
surgery, loco-regional treatments or orthotopic liver 
transplant. Moreover, HCC has a significant resistance 
to classic radio- or chemotherapy, that represent the 
standard of care in the majority of advanced tumors. 
Although the setting changed with the introduction of 
the multi-kinase inhibitor named sorafenib in 2008 for 
the treatment of advanced HCC, relevant issues in the 
management of this disease are still open. In particular, 
this therapy owns a wide variability in the prolongation 
of the survival of these patients. Furthermore, sorafenib 
therapy has some significant side effects and is very 
expensive. 
On this background, the aim of this review is to 
remind the main problems related to diagnosis, staging 
and treatment allocation in case of advanced HCC, 
the principal indications of sorafenib, how to evaluate 
and to predict the response to treatment and when a 
second line therapy is suitable.
DIAGNOSIS, STAGING AND TREATMENT 
ALLOCATION
The development of radiological techniques has radically 
changed the approach to the diagnosis of HCC in the past 
decade. According to the American HCC guidelines, in 
2005 a diagnosis of HCC without biopsy could be made 
in presence of a mass > 1 cm showing characteristic 
arterial enhancement, observed in two different imaging 
modalities, either biphasic computed tomography (CT) 
or magnetic resonance (MR)[6]. In the following years the 
diagnostic accuracy of a single tomographic contrasted 
technique has been largely validated. The last American 
guidelines published in 2011 made possible the diagnosis 
of HCC in a cirrhotic patient when a nodule > 1 cm 
shows arterial enhancement and portal/delayed phase 
“washout”, with the use of a single tomographic exam 
(CT or MR)[7]. Future guidelines may probably include 
the use of organ-specific contrast agents (CA), that have 
shown a high sensitivity in the detection of new HCC 
lesions and of post-surgical disease recurrence as well 
as a good potential in hypo-vascular HCC diagnosis[8-10]. 
This additional radiological advancement, which has been 
included in Japanese guidelines[11] and is currently used 
in clinical practice, might further reduce the diagnostic 
role of liver biopsy in HCC in the next years.
Many staging systems have been developed for HCC, 
and so far there is no international consensus for the 
use of a favored one. The barcelona clinic liver cancer 
(BCLC) is the staging system most widely endorsed 
in HCC evaluation[12]. It was developed in 1999 and 
refined during the following years[3,5,6,13,14]. Considering 
different parameters such as the tumor burden, the 
hepatic function and the presence of disease-related 
systemic symptoms, the BCLC individuates five different 
stages of disease and suggests the appropriate first line 
therapeutic strategy. Moreover, it considers the impact 
of treatment on overall survival (OS), linking the stage 
with the prognosis[3].
According to BCLC, advanced stage (BCLC-C) is 
defined by the presence of unresectable HCC with extra-
hepatic spread (metastases or lymph nodes involvement) 
and/or vascular invasion (portal or segmental invasion) 
and/or systemic symptoms, defined by an Eastern 
Cooperative Oncology Group[15] performance status 1 
or 2, with a liver function defined by a Child Pugh[16] 
stage not greater than B. It is easy to understand 
1042 May 18, 2015|Volume 7|Issue 8|WJH|www.wjgnet.com
Colagrande S et al . Advanced HCC and sorafenib treatment
how advanced stage HCC includes a heterogeneous 
population of patients, with different prognosis. For 
instance, the grade of liver function is significantly 
related to prognosis: patients with a Child Pugh B class 
have a shorter median survival (5 mo) than patients 
with more preserved liver function (7 mo)[5,17]. This 
stage of disease has been considered untreatable 
until 2008, when sorafenib has proven his efficacy in 
prolonging the survival of these patients in two different 
large studies[17,18]. Since then, sorafenib has become 
the suggested therapy for advanced HCC in the BCLC 
algorithm (Figure 1). 
Despite its wide use, the definition of advanced 
HCC by the BCLC and the allocation of sorafenib show 
some minor flaws. 
The first one is represented by the treatment of 
intermediate HCC, a stage of disease that includes a 
heterogeneous group of clinical presentations. Trans-
arterial chemo-embolization (TACE)[3,5] is the recom-
mended primary therapy for this stage, but some 
authors suggest its use also in selected BCLC-C patients 
with a better liver function[19,20]. Conversely some others 
consider TACE not safe in patients with so advanced 
disease and recommend this treatment only in patients 
with Child-Pugh A cirrhosis and segmental portal vein 
thrombosis[21]. Besides, the BCLC does not lead to a clear 
therapeutic indication for patients who cannot afford or 
have failed TACE. This problem has been partially solved 
through the introduction of the concept of “treatment 
stage migration”: if patients are not candidates for first-
line therapy as per stage, they can be shifted to the 
treatment option for a more progressed BCLC stage[3,5]. 
Translated in clinical practice, sorafenib should be 
administered also in intermediate HCC patients who 
can’t afford or have failed the treatment with TACE. 
At the same time TACE may be considered a suitable 
alternative for advanced stage HCC patients who are not 
compliant with oral therapy or could not have access to 
sorafenib[22]. In the last years even the combined use of 
sorafenib and TACE for intermediate and/or advanced 
HCC has been evaluated in different studies[23-25]. 
However, data published so far about safety and efficacy 
of this therapeutic regimen is controversial and a precise 
validation is still needed.
The second problem is related to the notion that 
BCLC defines as “advanced HCC” any patient presenting 
an Eastern Cooperative Oncology Group performance 
status of 1-2. In clinical practice, it means that patients 
could be excluded from potentially curative treatments 
if they are “restricted in physically strenuous activity 
but ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light house work, office work”[15]. 
In our judgment, this approach could seriously limit the 
clinical benefit in this particular kind of patients. It should 
be stressed that every therapeutic choice, especially 
in this kind of patients, deserves a multidisciplinary 
approach, as every disease represents an unique case. 
A relatively new promising therapeutic option for 
intermediate/advanced HCC is represented by trans-
arterial radio embolization (TARE). Differently from 
TACE, its main effect is not related to a mechanic 
obstruction of the arteries that feed the tumor: by the 
use of yttrium-loaded glass or resin particles a localized 
beta radiation of the mass can be obtained[26] (Table 1). 
Although there are some absolute contraindications, 
represented by a tumor burden over 75% of liver 
parenchyma and lung or gastrointestinal uncorrectable 
shunts[26] (that may lead to development of a radiation 
induced pneumonia), TARE has emerged as a safe 
treatment option and showed survival rates similar to 
TACE and sorafenib in studies published so far[27,28]. In 
particular this therapeutic option may be considered an 
interesting alternative to TACE, especially in patients 
with portal vein thrombosis[29]. However, data from 
randomized control trials are needed in order to confirm 
the therapeutic role of TARE for HCC in clinical practice. 
SORAFENIB TREATMENT 
Sorafenib still represents the only approved therapy 
for advanced HCC[5]. It is a multi-kinase inhibitor with 
anti-angiogenic and anti-proliferative effect. It acts by 
inhibiting the serine-threonine kinases Raf-1 and B-Raf 
and the receptor tyrosine kinase activity of vascular 
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Advanced stage (C)
Portal invasion
N1, M1, PST 1-2
Intermediate stage (B)
After TACE failure
After sorafenib failure
Second line therapiesChild-Pugh B
No PVT
Child-Pugh A
PVT
TACE
TARE
Sorafenib
Brivanib (BRISK-PS 2013)
Evrolimus (EVOLVE-1 2014)
Ramucirumab (REACH 2013)
Regorafenib (Bruix et al  2013)
Phase Ⅱ-Ⅲ clinical trials
Loco-regional therapies                                                               Systemic therapies
Figure 1  Main therapeutic options for advanced hepatocellular carcinoma treatment. TACE: Trans-arterial chemo-embolization; TARE: Trans-arterial radio 
embolization; PST: Performance status; PVT: Portal vein thrombosis.
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was low (7 out of 299)[17,38,39].
The increase in median OS was confirmed also in the 
second of the two abovementioned studies, conducted 
in China, Taiwan and South Korea on 226 advanced 
patients: mean OS was 6.5 mo in the treatment group 
against a 4.2 mo in the placebo arm[18]. Unfortunately 
the development of AE can reduce the compliance to 
therapy and worsen patient prognosis: in the SHARP 
study the incidence of AE was 70%-85% (vs 43%-60% 
in the placebo groups) but severe effects were observed 
in 9.4%-14.6% of patients[17]. The median duration of 
treatment was 5.3 mo (range, 0.2 to 16.1) and 176 of 
the patients in the sorafenib arm discontinued the study 
because of AE[17]. In both studies the most common 
significant AE causing a drug dose reduction (from 800 
to 400 mg/die) were Hand-Foot Syndrome (10%-11% 
of patients) and diarrhea (5%-7%)[18].
Recent studies suggest that a dose reduced regimen 
of 400 mg/die could be equally effective in prolonging 
OS[40]. This data should advise the use of a “softer” 
regimen in patients who are more likely to develop 
AE during sorafenib treatment (e.g., Child B7, elder 
patients). In those cases sorafenib could be started at 
reduced dose, e.g., 400 mg/die, and “ramped up” to 
600 or 800 mg/die if the patient shows a good profile 
of tolerability. Post-marketing clinical studies showed 
that only a portion of patients actually benefits from 
sorafenib treatment (Figure 2), and an even smaller 
percentage of patients treated shows partial/complete 
response on follow-up examinations (Figure 3), up 
against relevant costs and an incidence of drug related 
AE probably higher (24%-28% of severe AE) than 
reported in the SHARP and Asia Pacific studies[17,35,41]. 
Because of the problems related to the poor 
effectiveness of sorafenib and because of its cost, many 
studies tried to compare sorafenib to other commonly 
used treatments for unresectable HCC. Although, 
according to BCLC, TACE has no indication for advanced 
HCC, a study comparing this two different therapeutic 
options reported similar benefits from TACE and 
sorafenib in advanced stage HCC[42]. 
Association therapy of TACE and sorafenib has 
been investigated in some recent works that showed 
good results in term of safety and efficacy in BCLC-B 
patients[24,43], but its therapeutic role in BCLC-C 
patients is still unclear. In fact, most of the studies have 
shown that association therapy may improve time to 
progression, but it does not seem to improve OS if 
compared to TACE alone[44-47]. Conversely, Bai et al[48] 
have found some benefits in terms of OS, in patients 
treated with sorafenib plus TACE. This combination finds 
its theoretical physiological basis on the anti-angiogenic 
effect of the drug, in contrast with the physiological 
release of angiogenic factors consequent to the arterial 
iatrogenic obstruction[30]. Nevertheless the results about 
this kind of treatment are still uncertain[44]. 
In a recent study sorafenib has also been compared 
to TARE: median OS was similar in the two groups[49]. 
endothelial growth factor receptors 1, 2, and 3 and 
platelet-derived growth factor receptor β[30-32]. Sorafenib, 
according to technical schedule, can be prescribed in 
patients with preserved liver function (Child-Pugh A) 
and it should be orally administered at 800 mg/die (400 
mg twice a day). The therapy should be carried on until 
disease progression or unacceptable adverse effects 
(AE) occur[33]. Fatigue, diarrhea, hand-foot syndrome, 
bleeding, arterial hypertension and hepatic toxicity 
(represented by the elevation of transaminase and/or 
bilirubin) are some of the most frequent AE observed 
during treatment, and can compromise the quality of 
life during a therapy that in any case is palliative[34,35]. 
Sorafenib treatment cost varies from about 2600 to 
5300€ per month, depending on the dose (400 mg/die 
vs 800 mg/die), with a mean cost about 4079 United 
States dollars per month[36]. 
Although sorafenib is the only drug which has indi-
cation for advanced HCC, only a few patients obtain a 
real benefit from this therapy. In general, the outcome 
and the extent of therapy is also linked to liver function: 
Child B patients have lower survival than Child A ones[37].
In the two largest studies published so far, “SHARP” 
and “Asia-Pacific”, the main objective tumor response 
ratio according to Response Evaluation Criteria in Solid 
Tumors (RECIST) was only 2%-3% in the sorafenib 
group patients, and a stable disease was observed in 
34%-43% of patients, with an OS only three months 
longer than placebo group[17,18]. In fact, in the first of 
these phase Ⅲ studies conducted comparing sorafenib 
(at 800 mg/die) and placebo with a double blind fashion 
on a total of more than 600 patients with advanced 
HCC[17], this drug showed a significant improvement 
in terms of OS (median OS 10.7 mo vs 7.9 mo of the 
placebo control group) and of time to progression, but 
the number of partial responses in the treatment group 
Table 1  Main loco-regional therapies in advanced hepatocellular 
carcinoma treatment
Loco-regional therapies
TACE is the most common used loco-regional treatment in patients 
with unresectable HCC, without macrovascular invasion or extrahepatic 
spreads (BCLC stage B) 
The use of TACE in advanced HCC is controversial: some authors 
affirm its better efficacy in term of survival benefit, than the best 
supportive care in HCC with extrahepatic spreads and macrovascular 
invasion. Some other ones recommend to be careful and suggest its use 
only in selected patients with Child A cirrhosis and segmental portal 
vein thrombosis
TACE can be a valid alternative for advanced HCC patients who are not 
compliant with oral therapies or have severe side effects or could not 
have access to sorafenib because of health authorities or high cost 
In advanced HCC, TARE shows survival rates similar to sorafenib and 
TACE, especially in patients with portal vein thrombosis
TARE contraindication: important arterial shunt to gastrointestinal tract 
or lung, any contraindication to catheterization 
TACE: Trans-arterial chemo-embolization; TARE: Trans-arterial Radio 
Embolization; HCC: Hepatocellular carcinoma; BCLC: Barcelona clinic 
liver cancer.
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The extension of portal invasion resulted to be an 
important prognostic factor for the good result of TARE 
since patients with partial portal invasion of a branch 
of the vein had better prognosis than those who had 
disease extended to the main trunk[50]. The association 
of TARE and sorafenib has been investigated and showed 
good results in terms of safety, although data about OS 
with this combined therapy are still being investigated[51]. 
The physiological basis to combine these two therapies 
is that sorafenib seems to decrease the risk to develop 
a new lesion or distant metastasis, while TARE is more 
efficient in controlling primary hepatic lesion.
Ravaioli et al[52] reported two cases of advanced 
disease HCC that became suitable to liver transplantation 
after TARE treatment. TARE ability to downstage tumor 
has also been reported by other authors[53].
Over against its apparent simplicity, the treatment 
with sorafenib owns relevant open issues that can make 
the management problematic for the clinician. In fact, 
to reach a real benefit for the patients and to obtain a 
proper allocation of the money resources, it is crucial 
to identify a suitable method to evaluate response and 
hopefully early predictors of response and survival. 
BIOCHEMICAL RESPONSE EVALUATION 
PARAMETERS 
According to reported data we deduce that sorafenib 
therapy does not improve the prognosis in all advanced 
HCC patients and a part of responders have not such 
an important benefit to justify an expensive and rich 
in terms of AE therapy. Therefore, one of the primary 
objectives is to identify some biomarkers that may 
predict the efficacy of sorafenib treatment and may help 
the clinicians to select possible responder patients. 
To clarify this point, many studies have focused on 
serum anti-angiogenic factors concentration; in particular, 
in the SHARP study, Llovet et al[17] found that low baseline 
concentration of vascular endothelial growth factor-A 
(VEGF-A) and high baseline concentration of Ang-2 
correlated with a better OS in both arms of the study 
(sorafenib and placebo group). These data suggest that 
VEGF-A and Ang-2 are independent prognostic factors, 
but they have not a straight correlation with sorafenib 
therapy efficacy[54]. Similar results were shown in another 
study on patients treated with sorafenib and metronomic 
tegafur/uracil[55].The possible role of some cytokines 
Baseline                                                       One month
A
B
C
ADC value: 1501                                            ADC value: 1058
Figure 2  Computed tomography and magnetic resonance imaging examination at baseline and one month after the start of sorafenib therapy of patient 
showing progressive disease. A: Arterial phase computed tomography (CT); B: Venous phase CT; C: Magnetic resonance imaging diffusion weighted imaging. ADC: 
Apparent diffusion coefficient.
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[interleukin 6 (IL-6)/IL-8] as predictive biomarker of 
sorafenib treatment efficacy has also been evaluated, 
but no significant results have been found[56]. Some 
interesting, but preliminary results have been found 
using insulin-like growth factor-1 (IGF-1) baseline serum 
concentration: high IGF-1 blood levels seem to correlate 
with a better OS during anti-angiogenic therapy[57]. In 
the last years, great interest was devoted on serum 
alpha-fetoprotein (AFP) levels in HCC patients during 
systemic therapy: high basal levels of AFP generally 
correlate with a poor prognosis, both in intermediate and 
advanced HCC[54]. Personeni et al[58] analyzed a cohort 
of 85 patients treated with sorafenib and individuated a 
significant association between the decrease of > 20% 
in AFP in the first 8 wk and OS. Similar results have 
been found in other studies[59,60]. An important problem 
in the use of AFP as a biomarker is the difficulty in 
establishing a reference of percentage decrease (relatively 
to baseline values) as a cut-off to assess a response to 
therapy; in fact, an accepted worldwide threshold has 
not been defined, and the choice of this cut-off differed 
in the various studies, usually between 20% and 50%. 
Moreover, measuring the early change in AFP level seems 
to be a valid predictive factor only for patients who have 
higher baseline AFP serum level. For this reason, some 
authors suggest that only patients with pre-treatment 
AFP level > 200 microg/L are suitable for this analysis[61]. 
Despite the key role of AFP in diagnosis and follow-up of 
HCC, the effectiveness in outcome prediction during anti-
angiogenic treatment is not clear yet, and needs to be 
evaluated in future.
In general, countless field-practice studies have 
analyzed the possible role of other biochemical and 
clinical parameters in early evaluation of response to 
sorafenib[40,62-67], i.e., aspartate transaminase, alkaline 
phosphatase basal and on-going levels, as well as the 
development of AE such as hand-foot syndrome or 
diarrhea have been related to a significantly prolonged 
OS, that represents the ultimate goal of treatment in 
patients with advanced HCC. 
IMAGING RESPONSE EVALUATION 
PARAMETERS 
Evaluation by imaging is another important tool and 
is usually performed every 2-3 mo during sorafenib 
Baseline                                                       One month
A
B
C
ADC value: 1078                                            ADC value: 1906
Figure 3  Computed tomography and magnetic resonance imaging examination at baseline and one month after the start of sorafenib therapy of a patient 
showing partial response. A: Arterial phase computed tomography (CT); B: Venous phase CT; C: Magnetic resonance imaging diffusion weighted imaging. ADC: 
Apparent diffusion coefficient.
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treatment[68] by dynamic imaging (CT or MR contrast 
enhanced scan), applying the modified RECIST 
(mRECIST)[69]. 
The introduction of the mRECIST radically changed 
the approach to treatment response evaluation. While 
RECIST 1.1 is principally based on lesion dimensions 
without any consideration for tumoral vitality, mRECIST 
introduced the evaluation of the actual vital part of 
the lesions, which is the one that shows contrast 
enhancement at CT or MR. 
Although the efficacy of mRECIST in tumor response 
evaluation in comparison with old RECIST 1.1 during 
sorafenib treatment has been recently confirmed by 
different studies[70,71], these criteria, based on vital 
lesions size measurements in time, still have some 
limitations. In fact, since sorafenib mainly operates 
through an anti-angiogenic effect, considering only 
the diameter of the vital portion is inadequate for a 
proper response evaluation. Some other parameters, 
able to quantitatively assess intralesional vitality or 
vascularization, are necessary to integrate mRECIST 
in order to make tumour response evaluation more 
reliable. It is proven that not all tumour progressions 
at imaging translate into a decreased OS and some 
improvements in prognosis have been shown in 
absence of tumour burden reduction[17,72]. This means 
that, even considering the increase in median OS, only 
a part of patients actually shows appreciable benefits, 
and those whose life expectancy is increased by the 
treatment are difficult to individuate since they rarely 
show a decrease in terms of lesion size/conspicuity. 
In other terms, the response does not correlate, at 
least initially, with a change in lesion dimension, but 
more probably it brings some intralesional decrease in 
cellularity and/or vascularization changes[30,72,73].
In this direction, the analysis of new radiological 
parameters in evaluation of response to sorafenib has 
shown promising results, and many attempts to evaluate 
different tumoral characteristics, such as intralesional 
perfusion and cellular density, have been performed so 
far. 
Perfusion weighted imaging (PWI) is a relatively new 
MR/CT technique for qualitative and quantitative eva-
luation of the delivery of blood to biological tissues[74]. The 
importance of local changes in blood flow, angiogenesis 
and capillary permeability in cancer progression and 
treatment motivate the researchers’ increasing interest 
in PWI. The primary mechanisms for the cancer lesions 
enhancement are the filling of the vasculature with CA 
enhanced blood, and the diffusion of this CA from the 
blood into the extravascular-extracellular interstitial 
spaces; these phenomena are increased by tumoral 
angiogenesis. An increase in blood flow leads to a more 
rapid CA filling of the vessels, with faster changes in signal 
intensity/density while a greater blood or extravascular-
extracellular volume will increase the fraction of the 
voxel to be filled with CA[74,75]. In tumoral lesions the 
level of peak enhancement and the rate of passage 
of the extravasated CA back to the vessels, with a 
return of signal intensity/density to its baseline values, 
is altered. In order to use image signal intensities to 
track and analyze enhancement dynamics, in PWI it is 
necessary to form a temporally resolved series of images 
(multiple acquisitions on the same area) that tracks the 
signal/density changes in different times after the CA 
administration, in analogy to tracer studies in nuclear 
medicine[75,76]. CT PWI parameters evaluation have 
shown significant changes during sorafenib treatment, 
in particular with a reduction in intralesional mean transit 
time as possible consequence of the anti-angiogenic 
effect of the drug[68,76]. 
Simple parameters, which indirectly correlate with 
intralesional vascularization have also been elaborated: 
Ronot has recently presented that in follow-up during 
sorafenib treatment the use of CHOI criteria, based on 
intralesional density on arterial phase CT acquisition, has 
shown promising potentials in terms of tumor response 
evaluation, comparable to those of mRECIST, although 
with minor reproducibility[71]. 
Studies on perfusion changes during therapy were 
also developed in ultrasonography. Contrast enhanced 
ultrasound, a technique which is now available in a large 
number of centers, and that can be repeated more than 
once in the first weeks from the beginning of therapy 
has shown, despite some major limits (such as operator 
dependency and partial liver volume exploration) some 
promising results in early response evaluation during 
sorafenib treatment, since it is able to evidence changes 
in target lesions enhancement during treatment[77]. 
The role of MR diffusion weighted imaging (DWI) 
in response assessment has been evaluated as well 
with controversial results[78-80]. This MR technique is 
based on water diffusion, which is the inconsistent and 
random microscopic motion of molecules caused by 
thermal energy, also known as Brownian motion. Even 
the more basic DWI principles description is beyond 
the aim of this review. It is sufficient to know that 
DWI indirectly describes the cellular density and the 
architectural changes of a tissue[81,82]. In fact, if within a 
tissue or a tumor several cells and many architectural 
barriers are present (as fibrosis, edema, any type of 
disorders or derangements), water molecules have 
difficulties in free movements and so “diffusion” is low 
(and, in general, signal intensity increases). On the 
contrary, if the cellular density is low and environment 
homogeneous, water molecules freely move, “diffusion” 
is easy and in general signal intensity decreases[81]. 
DWI technique could then be able to show some 
intralesional changes that are not evident on standard 
CT/MR scans. As regards to early assessment by DWI, 
in general, some studies conducted on different tumoral 
lesions have shown that apparent diffusion coefficient 
(ADC) changes in the first few weeks of treatment may 
precede dimensional reduction since, early after the 
start of treatment, changes in cellularity and necrosis 
may occur[83-85]. Conversely to what has been observed 
in solid cancers during chemotherapy treatment[86], 
Schraml et al[79] found an unexpected decrease in 
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HCC mean intralesional ADC values in the first 3-4 
wk of sorafenib therapy (maybe due to some micro-
hemorrhagic intralesional injury), with a subsequent 
increase at 3 mo evaluation[79].
Also in case of DWI, the main limitation remains the 
large variability of data (both in different acquisitions 
and in different centers and scanners), which reduces 
the reproducibility of this technique[87,88]. However it 
has also been demonstrated that timing of imaging is 
relevant: changes in ADC could precede changes in 
tumor size but may even disappear after a certain time 
because of repair mechanisms such as edema decrease 
and necrosis organization[89,90]. The early changes 
in intralesional ADC described by Schraml et al[79] in 
advanced HCC could be expression of some intralesional 
temporarily changes, preceding an eventual dimensional 
reduction and expressing a possible sensitivity to 
sorafenib action[79]. 
Until now, none of the aforementioned radiological 
technique has been positively tested in a large number 
of patients, but the good results obtained so far are 
suggestive for a possible integration of some of these 
parameters to standard follow-up and response evaluation.
Even more important would be the prediction of the 
response based on pre-treatment examinations. This 
continues to be controversial. From a general point of 
view, tumors with necrotic areas, often surrounded by 
hypoxic but viable cells, were shown being less sensitive 
to ionizing radiation[91], more prone to aggressive behavior 
and probably less sensitive to cytotoxic agents[92]. 
In case of HCC, on the contrary to what reported for 
other solid tumors, higher ADC values on DWI baseline 
images could be related to a minor cellular density and 
a higher vascularization, and this could be somehow 
an index of treatment sensitivity (particularly in case of 
anti-angiogenic drug such as sorafenib itself), while low 
levels of intralesional ADC could correlate with a worse 
prognosis a poor response to treatment, as shown by 
some studies, since they could be expression of a poorly 
vascular lesion with high cellular density[80]. In these 
terms also a CT/MR pretreatment evaluation could give 
some additive information about tumor cellular density 
and vascularization, and maybe help stratifying patients 
in terms of anti-angiogenic therapies sensitivity. 
Data available in this field are still limited and con-
troversial, but more researches will certainly be made, 
as being able to identify patients with high probability 
of response before or shortly after the start of the 
therapy is strongly desirable.
Even if the first encouraging results will be confirmed 
in a larger scale, the addition of CT/MR perfusion 
parameters evaluation to a routinely liver study and then 
the quantitative evaluation on a per patient basis is not 
possible yet. The main problems related to perfusion 
studies are some technical difficulties and the acceptable, 
but suboptimal reproducibility of these parameters, 
particularly with MR; while the greatest limitation in DWI 
use is the mentioned large standard deviation of the 
measurements and then the low reproducibility[93,94].
SORAFENIB FAILURE AND SECOND-LINE 
THERAPIES 
As already mentioned, no other systemic treatment 
other than sorafenib have, so far, shown the capability 
to improve the OS in patients with advanced HCC. 
Despite the results in terms of survival during treat-
ment, only a very small percentage of patients actually 
shows benefits in terms of radiological staging[17,18], so 
it is still discussed whether sorafenib treatment should 
actually be prolonged also in case of tumor progression at 
first follow-up examinations[56,95]. Anyway, even in case of 
evident benefits from the treatment, most of the patients 
experience a loss of efficacy of the drug during time[96]. 
There is then a strong request from clinicians for an 
established second line therapy to propose to patients 
when sorafenib cannot be administered or has to be 
interrupted due to AE or loss of efficacy (Table 2).
Metronomic capecitabine has been largely used as 
second line treatment in patients showing progressive 
disease after sorafenib treatment mainly because of its 
high tolerability[97]. 
In the randomized controlled trial that compared 
brivanib vs placebo as second-line therapy after sorafenib 
failure[98], the improvement of time to progression 
observed in brivanib arm did not translated in an 
increased OS[72]. An interesting phase Ⅲ trial comparing 
sunitinib with sorafenib has shown similar results in 
terms of time to progression between the two drugs, but 
Systemic therapies
The only drug approved for the treatment of advanced HCC. Patients 
treated with sorafenib have longer OS then placebo group in the two 
largest studies
The efficacy of this treatment is linked to liver function: Child B patients 
have much lower survival than Child A ones (5.5 mo vs 11.3 mo). Child 
C patients have very poor prognosis and seem not to be suitable for 
sorafenib therapy (1.6 mo) 
Patient treated with sorafenib has longer survival than those treated 
with sunitinib. No difference in OS has been found comparing sorafenib 
treatment to brivanib 
Some combination therapies have been proposed, but none of these has 
shown superiority compared to sorafenib alone 
At now there is no therapeutic plan approved as second line in 
advanced HCC pretreated with sorafenib
Some drugs as capecitabine, brivanib, sunitinib, everolimus have 
been tested in monotherapy, moreover some combination therapies 
as erlotinib with sorafenib, and gemcitabine with oxaliplatin have 
been evaluated as second line options, but all of them have not given 
significant results
Many studies are still in progress and some interesting, but preliminary 
results have been obtained in patients with high expression of c-met in 
treatment with brivanib 
Table 2  Main systemic therapies in advanced hepatocellular 
carcinoma treatment 
HCC: Hepatocellular carcinoma; OS: Overall survival.
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with worse results for sunitinib in terms of survival[99]. 
The use of brivanib and the combination of erlotinib with 
sorafenib have also been tested but failed in phase Ⅲ 
trials[72,100-102]. 
From ongoing studies, the most promising results 
come from the observation of a significantly better 
outcome in patient with high expression of c-met treated 
with tivantinib[103]. From these data, a large phase Ⅲ trial 
in second line is currently ongoing. 
Although, it has been demonstrated that HCC patients 
who respond to TACE usually have poor response to a 
subsequent sorafenib treatment[104], as we mentioned 
above the possible role of the synchronous use of both 
therapies is also being investigated[105].
CONCLUSION 
Advanced stage HCC is a category of disease defined 
by clinical, functional and radiological parameters, 
comprehending a wide range of patients with different 
general conditions, but with poor prognosis and life 
expectancy. 
Since 2008 the main option for this stage of disease 
is represented by systemic treatment with sorafenib, 
that mainly shows an anti-angiogenic effect.
Although the treatment has shown an increase in 
OS in different studies, only a part of patients actually 
shows some benefits with a little percentage of partial 
response, while the incidence of drug related significant 
AE and the economic costs are high. 
Being able to properly differentiate responder from 
non-responder patients as early as possible is then a 
pivotal challenge and could spare several patients a 
therapy often difficult to bear, directing them to some 
other second line treatment, at now under investigation. 
For this reason, some supplemental parameters as 
biochemical and radiological prognostic factors are being 
searched for. In particular, finding some parameters 
quantitatively describing perfusion grade, and then able 
to predict the sensitivity of the lesions to anti-angiogenic 
agents could help in stratifying patients in terms of 
treatment responsiveness before the beginning of the 
therapy itself. 
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